Replimune's Coin Flip: A 10-3 Vote, a Missing Decision, and a Stock Levitating on Vibes

Here's a fun exercise: try to find the actual FDA decision on Replimune in this pile of catalysts. Go ahead, look. The PDUFA date was August 2, 2026. We're a day past it. And the loudest news in the file is still an advisory committee vote from late July. That's not a footnote — that's the whole story. REPL is trading on the memory of a vote, not the verdict of a regulator, and the desk should be very clear-eyed about what that means.

The setup: a great vote, a messy trial, and a monster rally

Let's give credit where it's due. A 10-3 favorable AdCom vote for RP1 plus nivolumab in advanced melanoma is a real, meaningful signal. Panels don't hand those out for sympathy. The stock responded the way stocks do when a binary biotech event breaks the right way: it ripped 132.9%. That's not a rally, that's a repricing of the entire company's existence.

But read the fine print bears keep pointing at, because it matters: the supportive data came from IGNYTE, a single-arm trial — historically exactly the kind of design that makes FDA reviewers twitchy, and exactly why the vote was 10-3 and not 13-0. Three dissenters on a panel this consequential isn't noise. Wedbush, sitting closer to the tape than most, raised its price target from $6 to $9 after the vote — a genuine vote of improved confidence — and still kept the rating at Neutral, explicitly citing lingering trial-design concerns and "limited confidence in near-term approval." That's a firm saying "better, not solved."

The math doesn't love you here

Strip away the AdCom euphoria and look at the balance sheet, because nobody's buying this for the fundamentals. Replimune posted a net loss of $3.38 per share for fiscal 2026, worse than the $3.27 the Street expected. ROE sits at -107.88%. Operating cash flow is bleeding -$172 million. Debt-to-equity is at 67%. This is a company with zero revenue, an accelerating burn rate, and a capital structure that is going to need more capital, full stop. If you're long REPL, you're not underwriting a business — you're underwriting a regulatory outcome and hoping the company can fund itself long enough to commercialize it.

And here's the part that should really give you pause: short interest is sitting at 30.53%. That's an enormous bet against a stock that just tripled on good news. Somewhere between "the panel loved it" and "the shorts are piling in," there's a real disagreement about what happens next — and disagreements this size, in a stock this volatile, tend to resolve violently in one direction.

The valuation gap nobody's reconciling

As of August 2, the Street consensus target sat at $14 against an $11.20 share price — 15 analysts, ~25% implied upside. Sounds bullish. But Wedbush's freshly-updated $9 target, and the prior Street average of $7.67, both sit below where the stock is trading. So you've got a consensus number pulled up by optimists who think approval is basically in the bag, sitting on top of a floor of skeptics who think the rally already overshot. Our own model's forecast band points toward $6.72 on the technical side even with RSI reading overbought — which is the market's way of saying "priced for perfection, positioned for disappointment."

Where this leaves you

REPL right now is a lottery ticket dressed up as a biotech stock. The AdCom vote bought real optionality — genuinely improved odds of approval — but it did not buy certainty, and the FDA has a documented habit of caring more about trial architecture than panels sometimes do. Layer on a $172 million annual cash burn, a balance sheet leaning on debt, and short interest north of 30%, and you have a stock where the risk/reward is not "modest upside, modest downside." It's binary. A CRL sends this back toward single digits fast; a clean approval could validate the rally and then some.

The August 6 earnings call was supposed to be the tell-all on cash runway — instead it now doubles as the venue where we finally find out if the FDA said yes. Until that number hits the tape, anyone telling you they know which way this breaks is selling something. Trade the binary if you must, but size it like the coin flip it actually is.